collaborators

1 paper

stat.AP2024

DEMO: Dose Exploration, Monitoring, and Optimization Using a Biological Mediator for Clinical Outcomes

Cheng-Han Yang, Peter F. Thall, Ruitao Lin

Phase 1-2 designs provide a methodological advance over phase 1 designs for dose finding by using both clinical response and toxicity. A phase 1-2 trial still may fail to select a…